Donald E Mager
Overview
Explore the profile of Donald E Mager including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
2757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ainslie K, Bowers A, Chichewicz R, Collier L, Doorn J, Frei C, et al.
AAPS J
. 2025 Feb;
27(1):41.
PMID: 39904863
On October 29, 2024, a virtual meeting, brought together chairs and vice chairs from several research-oriented U.S. Schools of Pharmacy to discuss the current landscape of pharmaceutical sciences, advocacy strategies,...
2.
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
Jarvi N, Patel M, Shetty K, Nguyen N, Grasperge B, Mager D, et al.
Front Immunol
. 2024 Dec;
15():1496169.
PMID: 39720710
Introduction: Immunogenicity continues to be a challenge for development and clinical utility of monoclonal antibodies, and there are gaps in our current ability to prevent anti-drug antibody development in a...
3.
Mohanan E, Shen G, Ren S, Fan H, Moua K, Karolak A, et al.
Clin Transl Sci
. 2024 Aug;
17(8):e70014.
PMID: 39162578
Dose optimization of sirolimus may further improve outcomes in allogeneic hematopoietic cell transplant (HCT) patients receiving post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD). Sirolimus exposure-response association studies in HCT...
4.
Kumar M, Lanke S, Yadav A, Ette M, Mager D, Shah D
Antibodies (Basel)
. 2024 Jul;
13(3).
PMID: 39051330
The objective of this work was to develop a population physiologically based pharmacokinetic (popPBPK) model to characterize the variability in the clinical PK of monoclonal antibodies (mAbs) following intravenous (IV)...
5.
Derippe T, Fouliard S, Decleves X, Mager D
CPT Pharmacometrics Syst Pharmacol
. 2024 May;
13(7):1252-1263.
PMID: 38747730
Both primary and acquired resistance mechanisms that involve intra-tumoral cell heterogeneity limit the use of BH3-mimetics to trigger tumor cell apoptosis. This article proposes a new quantitative systems pharmacology (QSP)-based...
6.
Ramakrishnan S, Cortes-Gomez E, Athans S, Attwood K, Rosario S, Kim S, et al.
Genome Med
. 2024 Apr;
16(1):52.
PMID: 38566104
Background: Prostate cancer is a significant health concern, particularly among African American (AA) men who exhibit higher incidence and mortality compared to European American (EA) men. Understanding the molecular mechanisms...
7.
Nguyen V, Zhang L, Kagan L, Rowland M, Mager D
J Pharm Sci
. 2023 Oct;
113(1):167-175.
PMID: 37871777
Drug effects are often assumed to be directly proportional to the fraction of occupied targets. However, for a number of antagonists that exhibit target-mediated drug disposition (TMDD), such as angiotensin-converting...
8.
Wang J, Chen T, Ruszaj D, Mager D, Straubinger R
J Pharm Sci
. 2023 Oct;
113(1):72-84.
PMID: 37844759
Therapeutic antibodies have shown little efficacy in the treatment of pancreatic ductal adenocarcinomas (PDAC). Tumor desmoplasia, hypovascularity, and poor perfusion result in insufficient tumor cell exposure, contributing to treatment failure....
9.
10.
Lin L, Ghasemi M, Burke S, Mavis C, Nichols J, Torka P, et al.
Target Oncol
. 2023 Aug;
18(5):685-695.
PMID: 37632592
Background: In patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), salvage chemotherapy regimens (e.g., rituximab, ifosfamide, carboplatin, and etoposide, R-ICE) yield poor outcomes. Carfilzomib, an irreversible proteasome inhibitor, can...